[Adalimumab for early rheumatoid arthritis - Chances and risks : Initial analyses of the OPTIMA study].

Zeitschrift fur Rheumatologie

PubMedID: 23685856

Schmalzing M. [Adalimumab for early rheumatoid arthritis - Chances and risks : Initial analyses of the OPTIMA study]. Z Rheumatol. 2013;72(6):606-7.
An abstract is not available. Please access the article through the links below.